Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

doi:10.1080/14728214.2021.2009800

Back to search

Article

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Expert opinion on emerging drugs - 1 Mar 2022

Solana-Altabella Antonio, Ballesta-López Octavio, Megías-Vericat Juan Eduardo, Martínez-Cuadrón David, Montesinos Pau

Abstract excerpt

INTRODUCTION: The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in one-third of patients with Acute Myeloid Leukemia (AML). Midostaurin, quizartinib, and gilteritinib have been approved in the last years for the treatment of AML, and more Tyrosine Kinase Inhibitors (TKIs) targeting FLT3 are b...

Topics

Antineoplastic Agents
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.